PHARMACOTHERAPY OF ALZHEIMER’S DISEASE: A REVIEWAbstract
Alzheimer’s disease, the most common cause of dementia is not a normal part of aging and worsens over time. The most common early symptom of Alzheimer’s is difficulty remembering newly learned information. Microscopic changes in the brain begin long before the first signs of memory loss. Two abnormal structures called plaques and tangles are prime suspects in damaging and killing nerve cells. Currently, there are five FDA-approved drugs that treat the symptoms of Alzheimer’s disease — temporarily helping memory and thinking problems in about half of the people who take them. But these medications do not treat the underlying causes of Alzheimer’s. In contrast, many of the new drugs in development aim to modify the disease process itself, by impacting one or more of the many wide-ranging brain changes that Alzheimer’s causes. These changes offer potential “targets” for new drugs to stop or slow the progress of the disease. Today, there is a worldwide effort under way to find better ways to treat the disease, delay its onset, and prevent it from developing. The current review looks into the current drug therapy for Alzheimer’s disease and the ongoing research into new drug targets which could treat the underlying pathology.
Sachin Satpute *, Vilas Shingare and Manthan Mehta
Department of Pharmacology, Topiwala National Medical College & B Y L Nair Ch. Hospital, Mumbai Central, Mumbai, Maharashtra, India
29 May, 2015
10 July, 2015
29 September, 2015
01 December, 2015